8-K: Vaxart Faces Nasdaq Delisting and Trading Suspension Over Minimum Bid Price Non-Compliance

Vaxart, Inc. has received a delisting notice from Nasdaq due to its failure to meet the minimum bid price requirement, leading to a trading suspension effective July 8, 2025, with plans to move to the over-the-counter market.

Summary

• Vaxart, Inc. received a delisting notice from Nasdaq on July 1, 2025, for failing to comply with the Minimum Bid Price Requirement (Nasdaq Listing Rule 5550(a)(2)).
• The company's common stock closing bid price had fallen below $1.00 per share for 30 consecutive business days.
• Vaxart was initially given until December 30, 2024, to regain compliance.
• An additional 180-day compliance period was granted until June 30, 2025, which also expired without compliance being regained.
• Trading in Vaxart's common stock (VXRT) on Nasdaq will be suspended at the open of trading on July 8, 2025.
• The company plans to timely request a hearing before a Nasdaq Hearings Panel by July 8, 2025, to appeal the delisting.
• A timely request for a hearing will stay the delisting process but will not stay the trading suspension.
• Vaxart expects its common stock to begin trading publicly on the over-the-counter (OTC) market on July 8, 2025, under its existing symbol VXRT.
• The company has applied to be traded on the OTCQX tier of the OTC Market, though approval is not assured.
• Vaxart is considering all options to regain compliance with the Minimum Bid Price Requirement.

Sentiment

Score: 2

Explanation: The sentiment is negative due to the imminent delisting from Nasdaq and the forced move to the less liquid OTC market, indicating a significant setback for the company's stock and investor confidence. While the company plans to appeal and seek OTCQX listing, these are reactive measures to a negative event.

Positives

• Vaxart plans to timely request a hearing before a Nasdaq Hearings Panel to appeal the delisting determination.
• The company is considering all options to regain compliance with the Minimum Bid Price Requirement.
• Vaxart expects its common stock to begin trading publicly on the over-the-counter market on July 8, 2025, under its existing symbol VXRT, aiming to maintain liquidity for shareholders.
• The company has applied to be traded on the OTCQX tier, which is a higher tier of the OTC Market, indicating an effort to maintain a more structured trading environment.

Negatives

• Vaxart received a formal delisting notice from Nasdaq due to non-compliance with the minimum bid price requirement.
• The company failed to regain compliance within the initial period (by December 30, 2024) and the extended 180-day period (by June 30, 2025).
• Trading of Vaxart's common stock on The Nasdaq Capital Market will be suspended at the open of trading on July 8, 2025.
• A timely request for a hearing will not stay the trading suspension, meaning the stock will move to OTC regardless of the appeal outcome until a Panel Decision reinstates trading.
• There is no assurance that the company will be approved for trading on the OTCQX tier.

Risks

• Consequences of the Delisting Notice, including potential negative impact on investor confidence and stock liquidity.
• Uncertainty regarding the results of the company's appeal to the Nasdaq Hearings Panel.
• Challenges in the company's ability to regain compliance with the Minimum Bid Price Requirement.
• Continuing operating losses, which could further strain financial resources.
• Uncertainty of market acceptance for the company's products.
• Reliance on third-party manufacturers, which introduces supply chain and quality control risks.
• Accumulated deficit, indicating historical financial losses.
• Future capital needs and uncertainty of capital funding, which may be exacerbated by delisting.
• Dependence on a limited product line and distribution channels.
• Competition within the industry.
• Limited marketing and manufacturing experience.

Future Outlook

Vaxart expects its common stock to begin trading publicly on the over-the-counter market on July 8, 2025, under its existing symbol VXRT. The company has applied to be traded on the OTCQX tier of the OTC Market, though approval is not guaranteed. Vaxart plans to request a hearing before a Nasdaq Hearings Panel and is considering all options to regain compliance with the Minimum Bid Price Requirement.

Management Comments

• The company plans to timely request a hearing before a Nasdaq Hearings Panel pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series.
• The company is considering all options with regard to its stock listing, including efforts to regain compliance with the Minimum Bid Price Requirement.
• The company expects that its common stock will begin trading publicly on the over-the-counter market on July 8, 2025, under its existing symbol VXRT.

Industry Context

This announcement reflects a specific compliance issue for Vaxart, Inc., rather than a broad industry trend. However, smaller biotechnology and pharmaceutical companies, particularly those in development stages without significant revenue, can frequently face challenges in maintaining stock prices above minimum listing requirements, making delisting a recurring risk in this sector.

Legal Proceedings

• The company plans to request a hearing before a Nasdaq Hearings Panel, which is a formal regulatory proceeding to appeal the delisting determination.

Stakeholder Impact

• Shareholders: Will experience a trading suspension on Nasdaq and a forced move to the over-the-counter market, which typically results in reduced liquidity, wider bid-ask spreads, and potentially lower stock valuation.
• Investors: May face challenges in trading shares and reduced visibility of the company's stock.

Next Steps

• Timely request a hearing before a Nasdaq Hearings Panel by July 8, 2025.
• Await a Panel Decision after the hearing regarding potential reinstatement of trading on Nasdaq.
• Begin trading publicly on the over-the-counter market on July 8, 2025.
• Continue efforts to regain compliance with the Minimum Bid Price Requirement.
• Await approval for trading on the OTCQX tier of the OTC Market.

Key Dates

Recommendation

Keywords

Vaxart, Nasdaq, delisting, minimum bid price, trading suspension, OTC market, 8-K filing, compliance, biotechnology, pharmaceuticals